Articles citing this paper
The subsidy of pharmaceuticals in Australia: processes and challenges
Lloyd Sansom
28(2) pp.194 - 205
37 articles found in Crossref database.
Bilateral trade agreements as drivers of national and transnational benefit from health technology policy: implications of recent US deals for Australian negotiations with China and India
Faunce Thomas, Shats Kathy
Australian Journal of International Affairs. 2008 62(2). p.196
A survey of reimbursement practices of private health insurance companies for pharmaceuticals not covered under the Pharmaceutical Benefits Scheme 2008
Lingaratnam Senthil M.,
Kirsa Sue W.,
Mellor James D.,
Jackson John,
Crellin Wallace,
Fitzsimons Michael, Zalcberg John R.
Australian Health Review. 2011 35(2). p.204
Social values and health priority setting in Australia: An analysis applied to the context of health technology assessment
Whitty Jennifer A., Littlejohns Peter
Health Policy. 2015 119(2). p.127
General practitioners' views on the influence of cost on the prescribing of asthma preventer medicines: a qualitative study
Tudball Jacqueline,
Reddel Helen K,
Laba Tracey-Lea,
Jan Stephen,
Flynn Anthony,
Goldman Michele,
Lembke Kirsty,
Roughead Elizabeth,
Marks Guy B., Zwar Nick
Australian Health Review. 2019 43(3). p.246
Understanding the Australian Health Care System (2009)
The Australian funding debate on quadrivalent HPV vaccine: A case study for the national pharmaceutical policy
Roughead Elizabeth Ellen,
Gilbert Andrew L., Vitry Agnes I.
Health Policy. 2008 88(2-3). p.250
Multifactor Analysis on the Income of Primary Health Care Institutions Implementing EMS in Hubei Province, China: A Cross-sectional Study
Yang Lianping,
Zhang Xinping,
Liu Wenbin, Wang Hongtao
Journal of Health Management. 2012 14(3). p.259
Why is the use of clopidogrel increasing rapidly in Australia? An exploration of geographical location, age, sex and cardiac stenting rates as possible influences on clopidogrel use
Ostini R.,
Hegney D.,
Mackson J. M.,
Williamson M., Tett S. E.
Pharmacoepidemiology and Drug Safety. 2008 17(11). p.1077
Promoting the consumer voice in palliative care: exploring the possibility of using consumer impact statements
McConigley Ruth,
Shelby‐James Tania, Currow David C
Health Expectations. 2015 18(5). p.653
Prices for Innovative Pharmaceutical Products That Provide Health Gain: A Comparison Between Australia and the United States
Roughead Elizabeth E.,
Lopert Ruth, Sansom Lloyd Norman
Value in Health. 2007 10(6). p.514
Recent developments in targeting access to high cost medicines in Australia
Lu Christine Y,
Ritchie Jan,
Williams Kenneth M, Day Richard O
Australia and New Zealand Health Policy. 2005 2(1).
Access to biologic medicines for the treatment of rheumatic diseases: lessons from Australia
LU Christine Y.,
WILLIAMS Ken, DAY Ric
International Journal of Rheumatic Diseases. 2008 11(1). p.11
Insights from Triangulation of Two Purchase Choice Elicitation Methods to Predict Social Decision Making in Healthcare
Whitty Jennifer A.,
Rundle-Thiele Sharyn R., Scuffham Paul A.
Applied Health Economics and Health Policy. 2012 10(2). p.113
Medicines and the media: news reports of medicines recommended for government reimbursement in Australia
Robertson Jane,
Walkom Emily J,
Bevan Marc D, Newby David A
BMC Public Health. 2013 13(1).
Uptake of medicines and prescribing patterns in the palliative care schedule of the Pharmaceutical Benefits Scheme
Currow David C, Sansom Lloyd N
Medical Journal of Australia. 2014 200(10). p.560
PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA
Turkstra Erika,
Bettington Emilie,
Donohue Maria L., Mervin Merehau C.
International Journal of Technology Assessment in Health Care. 2017 33(4). p.521
Setting priorities for high-cost medications in public hospitals in Australia: should the public be involved?
Gallego Gisselle,
Taylor Susan J., Brien Jo-anne E.
Australian Health Review. 2011 35(2). p.191
Provision of pharmaceuticals in Australian hospitals: equity of access?
Gallego Gisselle,
Taylor Susan J., Brien Jo-anne E.
Pharmacy World & Science. 2007 29(2). p.47
From Regulatory Approval to Subsidized Patient Access in the Asia-Pacific Region: A Comparison of Systems Across Australia, China, Japan, Korea, New Zealand, Taiwan, and Thailand
Cook Greg, Kim Hansoo
Value in Health Regional Issues. 2015 6 p.40
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal
Faunce Thomas A
Australia and New Zealand Health Policy. 2007 4(1).
The Pharmaceutical Benefits Scheme and implications for paediatric prescribing
Sinha Yashwant,
Brien Jo‐anne E, Craig Jonathan C
Journal of Paediatrics and Child Health. 2009 45(6). p.351
Patient access schemes in Asia-pacific markets: current experience and future potential
Lu Christine Y,
Lupton Caitlin,
Rakowsky Shana,
Babar Zaheer-Ud-Din,
Ross-Degnan Dennis, Wagner Anita K
Journal of Pharmaceutical Policy and Practice. 2015 8(1).
Pharmaceutical Benefits Scheme cost sharing, patient cost consciousness and prescription affordability
Doran Evan,
Robertson Jane, Salkeld Glenn
Australian Health Review. 2011 35(1). p.37
Generic Medicines in Australia: Business Dynamics and Recent Policy Reform
Lofgren Hans
SSRN Electronic Journal. 2009
A mathematical model for pharmaceutical supply chain coordination: Reselling medicines in an alternative market
Tat Roya,
Heydari Jafar, Rabbani Masoud
Journal of Cleaner Production. 2020 268 p.121897
Identification of Indicators for Evaluating the Financial and Economic Performance of the Pharmacy: A Systematic Review
Imani Ali,
Janati Ali,
Moghimi Mona,
Golestani Mina, Doshmangir Leila
Pharmaceutical Sciences. 2015 21(2). p.111
Costs of medicines and health care: a concern for Australian women across the ages
Walkom Emily J,
Loxton Deborah, Robertson Jane
BMC Health Services Research. 2013 13(1).
Tailoring access to high cost, genetically targeted drugs
Hall Wayne D,
Ward Robyn,
Liauw Winston S,
Brien Jo‐anne E, Lu Christine Y
Medical Journal of Australia. 2005 182(12). p.607
The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia
Lu Christine Y,
Ritchie Jan,
Williams Ken, Day Ric
Australia and New Zealand Health Policy. 2007 4(1).
Access to high cost medicines in Australia: ethical perspectives
Lu Christine Y,
Macneill Paul,
Williams Ken, Day Ric
Australia and New Zealand Health Policy. 2008 5(1).
The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines
Lu Christine Y,
Williams Kenneth M, Day Richard O
Australia and New Zealand Health Policy. 2007 4(1).
Public and Decision Maker Stated Preferences for Pharmaceutical Subsidy Decisions
Whitty Jennifer A.,
Scuffham Paul A., Rundle-Thiele Sharyn R.
Applied Health Economics and Health Policy. 2011 9(2). p.73
Hospital Drug and Therapeutics Committees in Australia: is there a role for economic evaluation at the institutional level?
Gallego Gisselle
International Journal of Clinical Pharmacy. 2011 33(6). p.895
Pharmaceutical Policy in Hong Kong: Defining an Evolving Area of Study
Chan Benjamin Tak-Yuen
SSRN Electronic Journal. 2009
Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada
Tett Susan E.,
Sketris Ingrid,
Cooke Charmaine,
van Zanten Sander Veldhuyzen, Barozzi Nadia
Pharmacoepidemiology and Drug Safety. 2013 22(7). p.735
A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand
Ragupathy Rajan,
Aaltonen Katri,
Tordoff June,
Norris Pauline, Reith David
PharmacoEconomics. 2012 30(11). p.1051
Accessing health outcome data on high‐cost medicines in Australia
Lu Christine Y,
Williams Kenneth M, Day Richard O
Medical Journal of Australia. 2006 184(8). p.411
